Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in <i>BRCA1</i> and/or <i>BRCA2</i> in the PROfound Trial
Joaquı́n Mateo, Johann S. de Bono, Karim Fizazi, Fred Saad, Neal D. Shore, Shahneen Sandhu, Kim N., Neeraj Agarwal, David Olmos, Antoine Thiery-Vuillemin, Mustafa Özgüroğlu, Niven Mehra, Nobuaki Matsubara, Jae Young Joung, Charles Padua, Ernesto Korbenfeld, Jinyu Kang, Helen Marshall, Zhongwu Lai, Alan Barnicle, Christian Poehlein, Natalia Lukashchuk, Maha Hussain
Abstract
Olaparib improved PFS and OS across subgroups of BRCA1/2mut #prostatecancer patients in the PROFOUND phase III trial.
Topics & Concepts
OlaparibMedicineProstate cancerOncologyInternal medicinePARP inhibitorCancerClinical trialProstateGynecologyPoly ADP ribose polymeraseGenePolymeraseChemistryBiochemistryPARP inhibition in cancer therapyProstate Cancer Treatment and ResearchCell death mechanisms and regulation